Table 2 Dose levels and dose-limiting toxicities

From: Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies

Dose level Dosing Number of patients Number of patients with dose-limiting toxicities (event)
1 50 mg m−2 paclitaxel +
400 mg pazopanib +
1000 mg lapatinib
7 1 (grade 3 ALT and grade 3 AST increased)a
2 50 mg m−2 paclitaxel +
800 mg pazopanib +
1000 mg lapatinib
3 0
3 80 mg m−2 paclitaxel +
800 mg pazopanib +
1000 mg lapatinib
3 2 (grade 4 neutropeniab in one patient and grade 3 fatigue in one patient)
4 80 mg m−2 paclitaxel +
400 mg pazopanib +
1000 mg lapatinib
13 2 (grade 4 thrombosis in one patient and grade 2 ALT and grade 3 AST increased in one patient)a
  1. Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase.
  2. aStart of cycle 2 delayed >2 weeks.
  3. bLasted >5 days.